Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
100 million volume reached
Vwap - 4.85
Auto vol 13 million
+41 + 11%
Expecting some large delayed kippers pm
Let’s see how the pm & weeks ahead pan out
100% + in last few weeks .
More importantly than the above - long term CAR T clinical nailed with Prevail underpinning
Friday clinical Grog for all invested
These bozo traders turn up late to the party & have to pay a premium in Hemo , Eua , etc & want to blame anyone but themselves for there poor choices
The info I post is from sources noted , try doing your own research & take responsibility for your own investment decisions ,
Pathetic human specimens for sure .
They spring up like Toxic blow up dolls in the back of Del boys van
Generally on these boards ..
Unfortunately when a quality stock begins to bag , you get the poisonous toads turning up with keyboard in one hand & small pecker in the other , green with envy & reeking of agenda
Greed brings the worst out in human behaviour & plenty on these chat forums for sure ,
I am a dad m grandad & live on a boat , hence the nautical banter - some just don’t get it , it’s harmless humour while we all try to make a few quid .
Only the beginning for CAR T & Hemo investors
With CBR & CD X still cooking
Fetch the finest Grog
Popped up on Ortex - words out on Hemo
Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases
- US Food & Drug Administration has lifted clinical hold on company's investigational new drug application for Hemo-Car-T to treat acute myeloid leukemia.
FDA placed therapy on clinical hold in July due to a splicing deficiency during manufacture of the lentivirus used to produce Car-T cells.
Hemogenyx in August produced a "detailed plan, supported by laboratory tests" to address FDA's concerns, which was accepted the following month.
Company says on Friday that the FDA has confirmed that all issues identified in its clinical hold letter have been satisfactorily addressed. FDA therefore consents to Hemogenyx proceeding with its phase 1 clinical study of Hemo-Car-T.
Chief Executive Officer Vladislav Sandler comments: "We are extremely pleased with the FDA's decision to lift the clinical hold. We now look forward to accelerating clinical development of Hemo-Car-T and to offering patients a potentially life-saving treatment."
Current stock price: 4.6 pence, up 16% on Friday morning
12-month change: 100% +
The word will be getting out there on Hemo science & subsequent stock re rate
Fetch the Grog
A couple of nice delayed kippers slapped on deck
Auto volume 11.5 million - currently
Date Time Trade Prc Volume Buy/Sell Bid Ask Value
09-Feb-24 09:28:34 4.82 700,000 Unknown* 4.31 4.50 33.74k O
09-Feb-24 09:28:01 4.875 588,973 Unknown* 4.31 4.50 28.71k O
Current stock 4.50 +16%
Huge volume pushing 90 million
Vwap 4.91 - barely shifted in last hour
Would expect a pm push & some huge delayed kipper trades later on
Great RNS & just the beginning on CAR T clinical with Prevail stood behind underpinning any deals .
Fetch the CAR T Grog
Generally on these boards ..
Unfortunately when a quality stock begins to bag , you get the poisonous toads turning up with keyboard in one hand & small pecker in the other , green with envy & reeking of agenda
Greed brings the worst out in human behaviour.
Only the beginning for CAR T & Hemo investors
With CBR & CD X still cooking
Fetch the finest Grog